Medicaid Drug Rebate Program and Generic Market Considerations

This technical report discusses the Medicaid Drug Rebate Program (MDRP) and its implications for generic drugs in the US healthcare system. It outlines the requirements for generic manufacturers under the MDRP, which mandates rebates in exchange for guaranteed coverage of outpatient prescription drugs. The report details the challenges faced by generic manufacturers, particularly regarding the inflation rebate that applies when a drug's average manufacturer price (AMP) increases faster than inflation. Five scenarios are presented where a generic manufacturer may incur an inflation rebate without raising drug prices, including changes in customer base and seasonal fluctuations in product usage. The report also highlights the unique dynamics of the multi-source generic market, which can lead to price competition and thin profit margins. The findings emphasize the potential for generic products to become unprofitable under the current rebate structure, resulting in product withdrawals and reduced market competitiveness.